PMV Pharmaceuticals, Inc.
PMVP
$1.56
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.49% | -12.73% | -19.18% | -18.11% | -2.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.75% | 2.90% | 13.43% | 22.38% | -1.88% |
| Operating Income | -3.75% | -2.90% | -13.43% | -22.38% | 1.88% |
| Income Before Tax | 21.69% | -9.99% | -21.97% | -28.57% | -45.97% |
| Income Tax Expenses | -- | -108.11% | 100.03% | -- | 100.00% |
| Earnings from Continuing Operations | 21.58% | -9.53% | -1,648.56% | -14.18% | -45.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.58% | -9.53% | -1,648.56% | -14.18% | -45.98% |
| EBIT | -3.75% | -2.90% | -13.43% | -22.38% | 1.88% |
| EBITDA | -3.79% | -4.53% | -15.40% | -24.73% | 0.19% |
| EPS Basic | 23.63% | -6.60% | -1,627.97% | -13.07% | -44.78% |
| Normalized Basic EPS | -7.09% | -7.02% | -20.70% | -32.55% | -3.13% |
| EPS Diluted | 23.63% | -6.60% | -1,627.97% | -13.07% | -44.78% |
| Normalized Diluted EPS | -7.09% | -7.02% | -20.70% | -32.55% | -3.13% |
| Average Basic Shares Outstanding | 2.67% | 2.75% | 1.03% | 0.98% | 0.83% |
| Average Diluted Shares Outstanding | 2.67% | 2.75% | 1.03% | 0.98% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |